🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million new cases annually. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Authorization

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This authorization signifies a major breakthrough in the treatment of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Outcomes and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which combines an injection and a pill. The research involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Clinicians directly involved have expressed positive views. The availability of a easy-to-administer therapy of this kind is seen as a "revolutionary step" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.